Best Life Sciences Companies in Charlottesville, United States
The 44 best Life Sciences companies in Charlottesville, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Rivus Pharmaceuticals.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Charlottesville
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Rivus Pharmaceuticals Developer of therapeutics for cardio-metabolic disorders | $233M | 19 mo ago | 12 | Allen Cunningham CEO | — | — | — | 1 launch |
| 2 | HemoShear Therapeutics Developer of novel biological targets and drugs for the treatment of rare metabolic disorders and NASH | $62M | 34 mo ago | 62 | Brian Wamhoff Co-Founder & CEO | — | — | — | — |
| 3 | TearSolutions Topical therapeutics for the treatment of dry eye disease | $37M | 9 mo ago | 9 | — | — | — | 38 patents Therapeutic peptide formulations for dry‑eye ocular treatment and pancreatic islet support | — |
| 4 | Restorgenex Developing mTOR pathway inhibitor for age-related macular degeneration & glioblastoma | $36M | 145 mo ago | — | David Kalergis CEO & Chairman | — | — | — | — |
| 5 | Indoor Biotechnologies Allergen expertise: purified allergens, test kits, testing services, and contract research 37Tech top 32%Moat top 38%Funding top 42%Growth top 45% All 10 signals ▾Techtop 32% Moattop 38% Fundingtop 42% Growthtop 45% Producttop 46% Talentbottom 49% Patentsbottom 45% Innovationbottom 42% Globalbottom 40% Marketbottom 29% Tech: 43 technologies across 5/8 capability areas · Cloud: Amazon Alb, Amazon S3 Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents rank vs industry peers · Fliar Intelligence Index 37/100 | $33M | 11 mo ago | — | Martin Chapman Chief Executive Officer | WordPressAlgoliaMySQL+29 | Top 10M | 9 patents Patents concentrated in chemistry & materials | — |
| 6 | ZielBio Developer of targeted therapeutics for cancer | $26M | 83 mo ago | 10 | Kimberly A. Kelly CEO & CSO | — | — | 7 patents Anti‑plectin‑1 monoclonal antibodies for cancer diagnosis and therapy | — |
| 7 | BrightSpec Provider of molecular rotational resonance spectroscopy technology 32Moat top 25%Innovation top 35%Patents top 36%Funding top 37% All 8 signals ▾Moattop 25% Innovationtop 35% Patentstop 36% Fundingtop 37% Talentbottom 49% Globalbottom 40% Techbottom 33% Marketbottom 27% Moat: Editorial + unicorn rating 7/10 · IP moat: 31 patents Innovation: 31 patents (top 41% of patent-holders) · 18 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $25M | 13 mo ago | 13 13 → 26 (+100%) | Dave Mcdaniel Co-founder and Chief Software Officer | — | — | 31 patents Analytical instruments for low‑volatility sample introduction and molecular rotational spectroscopy | — |
| 8 | Hemosonics Developer of viscoelastic testing systems for hemostasis assessment and bleeding management | $25M | 114 mo ago | 100 | — | WordPressMySQLPHP+38 | Top 10M | 120 patents Ultrasound-based devices for measuring blood coagulation and tissue mechanical properties | 1 launch |
| 9 | LumaCyte Provider of microfluidic and optics based instruments | $20M | 35 mo ago | 28 | — | WordPress Block EditorwpBakeryWordPress+29 | Top 50M | 87 patents Patents concentrated in transport & manufacturing processes | — |
| 10 | Contraline Developer of a male contraceptive hydrogel device | $19M | 11 mo ago | 7 | Kevin Eisenfrats Co-Founder & CEO | Contentfulstyled-componentsGatsby+7 | Top 5M | 55 patents Male contraceptive implant devices and controlled biomaterial delivery systems | — |
| 11 | TAU Therapeutics Developer of calcium T-channel therapies for solid tumors | $13M | 146 mo ago | — | Andrew J. Krouse Co-Founder | — | — | — | — |
| 12 | Caretaker Wireless Vital Signs Remote Monitoring Solution | $11M | 41 mo ago | 14 | Jeff Pompeo President & CEO | WordPressMySQLPHP+18 | Top 50M | — | — |
| 13 | GenEp Developer of therapeutics for the treatment of epilepsy | $10M | 25 mo ago | — | Andrew Krouse CEO | — | — | 8 patents Imidazole-based sodium channel inhibitor pharmaceuticals for neurological disorder treatment | — |
| 14 | OpenQ Compliant KOL Management Software | $8M | 182 mo ago | 52 | — | — | — | 4 patents AI-driven enterprise compliance monitoring of social media content | — |
| 15 | Gene Solutions Pioneering mitochondrial medicine, developing therapeutics for neurodegenerative and muscular diseases | $6M | 92 mo ago | 4 | David Patteson Co-Founder & Chairman | — | — | — | — |
| 16 | Retivue Innovative retinal screening solutions for early eye disease detection and blindness prevention | $6M | 16 mo ago | 5 | Paul Yates Founder & CEO | — | — | 26 patents Wide-field ophthalmic imaging systems and dual-camera endoscopic devices for retinal diagnostics | — |
| 17 | Gencia Biotech Biopharma company developing small-molecule mitochondrial agonists of the glucocorticoid receptors | $6M | 157 mo ago | — | Allen Cunningham Co-Founder & CEO | — | — | — | — |
| 18 | Liquet Medical Provider of a platform for localized drug delivery system | $3M | 5 mo ago | 4 | — | — | — | — | — |
| 19 | Neoantigenics Antibody-based therapeutics and molecular diagnostics for cancer | $3M | 138 mo ago | — | Brian Pollok Founding CEO | — | — | — | — |
| 20 | AMPEL Provider of bioinformatics platform for drug development | $3M | 44 mo ago | 33 | Amrie Grammer Founder | WordPressMySQLPHP+16 | Top 50M | — | — |
| 21 | KeViRx Developer of small molecule therapeutics for cancer | $3M | 27 mo ago | 3 | John Lazo Co-Founder | — | — | — | — |
| 22 | Cerillo Provider of microplate readers laboratory instrument systems | $2M | 18 mo ago | 24 24 → 21 (-12%) | Eric Mayton Chief Executive Officer | — | — | 30 patents High‑throughput solid‑state optical measurement and modular well‑plate lab automation systems | — |
| 23 | DiaKine Therapeutics Immune modulators for the treatment of diabetes and its related complications | $2M | 215 mo ago | — | Keith DiaKine Ex-President & CEO | — | — | — | — |
| 24 | SoundPipe Provider of catheter mounted ultrasound device to improve drug delivery | $975K | 52 mo ago | 10 | Joseph Kilroy Co-Founder & CEO | — | — | — | — |
| 25 | Vasarya Developer of site-specific fibrosis therapies targeting extracellular matrix mechanoswitches | $652K | 23 mo ago | — | Tom Barker Co-Founder & CSO | — | — | — | — |
| 26 | Atelerix Developer of small-molecule therapeutics for opioid addiction | $650K | 46 mo ago | 5 | James Bates Co-Founder | — | — | — | — |
| 27 | icarus Provider of knee brace technology | $620K | 57 mo ago | 36 | Dave Johnson Founder & CEO | WordPressMySQLPHP+27 | Top 5M | 11 patents Hybrid solar PV‑thermal panels with integrated heat recovery, storage, and cooling | 3 launchs |
| 28 | TypeZero Technologies Device for continuous glucose monitoring with manually operated insulin delivery | $415K | 134 mo ago | 3 | — | — | — | — | — |
Top 12 Life Sciences companies in Charlottesville
#1
Series B · Charlottesville, Virginia · founded 2013 · 9 employees$36.9Mraised▾
TearSolutions develop topical therapeutics for the treatment of dry eye disease. Its lead product is a proprietary synthetic fragment of the protein lacritin. The company claims that Lacripep is equipotent with natural lacritin and can alleviate dry-eye symptoms for up to 16 hours. Its currently in phase I clinical trials.
- Oct 2025Series B$517K
- Sep 2024Series B$12.7M
- Sep 2023Series B$390K
- Jul 2021Series B$5.6M
#2
Series B · Charlottesville, Virginia · founded 2019 · 12 employees$233Mraised▾
Developer of therapeutics for cardio-metabolic disorders. The company's lead candidate HU6 is a controlled metabolic accelerator for the treatment of type 2 diabetes, severe hypertriglyceridemia, non-alcoholic steatohepatitis, and heart failure with preserved ejection fraction.
- Jan 2025Series B$57M
- Aug 2024Series B$66M
- Sep 2022Series B$132M
- Jun 2021Series A$35M
#3
Funding Raised · Charlottesville, Virginia · founded 1995$32.7Mraised▾
Allergen expertise: purified allergens, test kits, testing services, and contract research. This company specializes in manufacturing highly purified proteins and immunoassays for research and diagnostics. Recognized as a world leader in assessment of environmental exposure to allergens, they combine academic expertise with practical experience. They offer a broad range of products and services, including purified allergens, advanced test kits, environmental and food allergen testing, and contract research for specialized needs. The company serves diverse markets, including pharma, diagnostics, academic and government researchers, cleaning and consumer product R&D, industrial hygiene, indoor air quality, and foods. Their offerings include testing services for dust and air allergens, endotoxins, enzymes, food allergens, lab animal allergens, mass spectrometry, cytokine analysis, western blotting, and viral immunoassays. They also provide biomanufacturing and preclinical CRO services. The company is committed to R&D and offers direct contact with their scientific team, fostering flexible, collaborative relationships.
- Sep 2025Grant (prize money)$8.8M
- Jul 2020Grant (prize money)—
- Aug 2011Grant (prize money)$8M
- Aug 2009Grant (prize money)$8M
#4
Seed · Charlottesville, Virginia · founded 2020 · 4 employees$3.3Mraised▾
Provider of a platform for localized drug delivery system. The company product can be used for drug delivery in the human vascular system.
- Mar 2026Seed$75K
- Dec 2024Seed$1.1M
- Dec 2023Seed$615K
- Apr 2023Seed$405K
#5
Series A · Charlottesville, Virginia · founded 2015 · 7 employees$18.6Mraised▾
Developer of a male contraceptive hydrogel device. The ADAM is a non-surgical, non-hormonal, and reversible birth control for men. It isultrasound-visible polymer solution that is injected into the vas deferens. Echo-V& forms a hydrogel device that acts as a semi-permeable membrane, blocking sperm while allowing fluids through.
- Sep 2025Grant (prize money)$1.4M
- Sep 2024Grant (prize money)$291.4K
- Nov 2022Series A$7.2M
- Oct 2021Series A$10.7M
#6
Series C · Charlottesville, Virginia · founded 2012 · 13 employees$25Mraised▾
Provider of molecular rotational resonance spectroscopy technology. It offers novel analytical instruments for direct, quantitative analyses of VOCs (volatile organic compounds) in a complex mixture, and for chiral analysis. It also offers analytical services by using the BrightSpec FT-MRR spectrometer platforms. It involves in pharmaceutical small molecule discovery and process R&D groups, fine chemicals solution providers, and academic and government research organizations.
- Jul 2025Grant (prize money)$1.2M
- Apr 2025Series C$3.9M
- Mar 2025Grant (prize money)$1.6M
- Mar 2023Grant (prize money)$1.7M
#7
Funding Raised · Charlottesville, Virginia · founded 2011 · 5 employees$5.9Mraised▾
Innovative retinal screening solutions for early eye disease detection and blindness prevention. They develop affordable, high-definition retinal imaging technology with a wide field of view to assist ophthalmologic professionals in documenting early eye disease and preventing blindness. Their EntireEye Imaging System allows for non-contact, non-mydriatic, high-definition image capture. They offer both portable and desktop options, providing imaging solutions for diverse populations. Their goal is to become the standard equipment used for eye screening through high-quality images, ease of use, portability, and affordability. They aim to improve access to and outcomes from eye screening by improving the ability to document eye disease in the retinal periphery, while simultaneously reducing cost and simplifying device use. Their technology supports tele-ophthalmic screening, enabling efficient reach to potentially affected patients at remote locations. They address the need for improved documentation of early-stage eye disease with user-friendly and cost-effective solutions.
- Apr 2025Grant (prize money)$745.6K
- Jun 2024Grant (prize money)$350K
- Sep 2017Grant (prize money)$1.8M
- Sep 2013Grant (prize money)$3M
#8
Seed · Charlottesville, Virginia · founded 2016 · 24 employees$2.2Mraised▾
Provider of microplate readers laboratory instrument systems. The company's flagship product is the Stratus, a portable, miniaturized microplate reader for the measurement of samples. It has applications for Bacterial Growth/Density, Protein Quantification, and Enzyme-linked Immunosorbent Assay(ELISA).
- Feb 2025Seed$1.1M
- Oct 2023Seed$1.4M
- May 2022Seed$875K
- Sep 2018Grant (prize money)$1.1M
#9
Series D · Charlottesville, Virginia · founded 2008 · 62 employees$62.4Mraised▾
Developer of novel biological targets and drugs for the treatment of rare metabolic disorders and NASH. The company has developed biological human disease models to understand the biological mechanisms of disease. Its proprietary platform, REVEAL-TX can recreate human disease models using tissue from sick patients. Its drug discovery programs in development are for rare metabolic disorders (propionic acidemia and methylmalonic acidemia) and non-alcoholic steatohepatitis (NASH).
- Oct 2023Conventional Debt$3.5M
- Feb 2021Series D$43.1M
- Feb 2020Series C$2.3M
- Jul 2018Series C$200K
#10
Series A · Charlottesville, Virginia · founded 2021$10.4Mraised▾
Developer of therapeutics for the treatment of epilepsy. The company aims to create therapies targeting mutations of sodium and other ion channels that cause rare genetic epilepsies and other treatment-resistant epilepsies.
- Jul 2024Series A$4M
- May 2023Series A$5M
- Oct 2021Seed$1.4M
#11
Series B · Charlottesville, Virginia · founded 2012 · 28 employees$19.8Mraised▾
Provider of microfluidic and optics based instruments. The company's proprietary product Radiance is a label-free microfluidic cell analyzer and sorter that allows characterization and sorting of individual cells by measuring their optical force and it has tremendous application for vaccine development in both R&D and manufacturing including viral infectivity assays. The ability to automate data collection on the viral infectivity of cells while improving results, reducing cost and time is invaluable for developing and producing vaccines.
- Sep 2023Series B$13M
- Mar 2022Series A$6.8M
- Jan 2021Seed$550K
- May 2019Seed$1.2M
#12
Funding Raised · Charlottesville, Virginia · founded 2022$652.2Kraised▾
Developer of site-specific fibrosis therapies targeting extracellular matrix mechanoswitches. This approach enables anti-fibrotic and regenerative potential by focusing on the extracellular matrix. The company's technology has the potential to develop a pan-fibrosis treatment. A strong leadership team with extensive experience in fibrosis research and biotech start-ups guides the company's development efforts. The company is supported by non-dilutive grants and investment partners.
- Sep 2024Grant (prize money)$356.2K
- Jun 2024Grant (prize money)$295.9K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.